Cell Signaling and Metabolism: Bridging a Gap in Cancer Therapies

Wed, Oct 24, 2018 2:30 PM EDT{LOCAL_TZ}

Cell Signaling and Metabolism: Bridging a Gap in Cancer Therapies

That cancer cells display an altered metabolism has been known for almost a century, but the cell-signaling mechanisms responsible for this phenomenon are just beginning to be understood, with some drugs targeting key regulators of both cell metabolism and tumor progression. The repurposing of old drugs for the activation and/or inhibition of proteins at the center of the cell-signaling and metabolism web has been a popular strategy for addressing these challenges. Drugs like metformin, chloroquine, and various statins are just a few examples of those in clinical trials. They offer a cost-effective advantage in addition to an already-established pharmacokinetic and pharmacodynamic profile. To further explore cell metabolism as a novel avenue of drug discovery based on already-established cell signaling mechanisms essential for tumor progression, The Scientist is bringing together a panel of experts to discuss their research into this exciting and recently acknowledged hallmark of cancer.

Topics to be Covered:
  • Metabolic symbioses in tumor microenvironments
  • Uncovering metabolic bottlenecks in genetic subtypes of lung cancer

M. Celeste Simon, PhD
Scientific Director and Investigator, Abramson Family Cancer Research Institute; Associate Director-Shared Resources, Abramson Cancer Center;
Rubenstein Professor, Dept. of Cell and Developmental Biology, University of Pennsylvania Perelman School of Medicine
Thales Papagiannakopoulos, PhD
Assistant Professor, Department of Pathology
NYU School of Medicine

close log in form button
Log In Now Not Registered?

close register form button
Register Now Already Registered?